glp-1 hfpef Receptor Agonists Among Patients With Overweight or Obesity, Diabetes, and on SGLT2 Inhibitors Early trials of GLP-1 based
Description
Branded injectables may be expensive without coverage
[DOI] [PubMed] [Google Scholar] 131.Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al
2025;69(1):e6
In essence, GLP-1 RAs like liraglutide may improve cognitive function and reduce dementia risk in some patients, but more research is needed to confirm these findings due to variability in study outcomes
